103 related articles for article (PubMed ID: 20734863)
1. [Urokinase-type plasminogen activator and its inhibitor type 1 in the diagnosis of evolving complications in coronary heart disease].
Pal'tseva EM; Rodina AV; Andreev DA; Popova ON; Gusev DE; Severin SE; Syrkin AL
Klin Lab Diagn; 2010 Jun; (6):51-5. PubMed ID: 20734863
[TBL] [Abstract][Full Text] [Related]
2. Urokinase plasminogen activator system in humans with stable coronary artery disease.
Krasnikova TL; Parfyonova Y; Alekseeva IA; Arefieva TI; Mukhina SA; Dobrovolsky AB; Titaeva Y; Lyakishev AA; Resink TJ; Erne P; Tkachuk VA
Clin Exp Pharmacol Physiol; 1999 Apr; 26(4):354-7. PubMed ID: 10225148
[TBL] [Abstract][Full Text] [Related]
3. [Relationship between atherosclerotic plaque characteristics and extracellular matrix metalloproteinase inducer and urokinase-type plasminogen activator in patients with coronary artery disease].
Yang L; Tian X; Guo R; Liu H; Qi F; Ye J
Zhonghua Xin Xue Guan Bing Za Zhi; 2014 Sep; 42(9):740-3. PubMed ID: 25511093
[TBL] [Abstract][Full Text] [Related]
4. [The plasma levels of urokinase plasminogen activator and urokinase plasminogen activator receptor and plasminogen activator inhibitor-1 in patients with different stages of liver cirrhosis following chronic hepatitis B].
Wu XR; Wang Q; Shi SS; Lu MH; Guo WD
Zhonghua Gan Zang Bing Za Zhi; 2004 Feb; 12(2):82-4. PubMed ID: 14980106
[TBL] [Abstract][Full Text] [Related]
5. Expression of urokinase plasminogen activator and plasminogen activator inhibitor type-1 in ovarian cancer and its clinical significance.
Zhang W; Ling D; Tan J; Zhang J; Li L
Oncol Rep; 2013 Feb; 29(2):637-45. PubMed ID: 23174953
[TBL] [Abstract][Full Text] [Related]
6. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.
Jänicke F; Prechtl A; Thomssen C; Harbeck N; Meisner C; Untch M; Sweep CG; Selbmann HK; Graeff H; Schmitt M;
J Natl Cancer Inst; 2001 Jun; 93(12):913-20. PubMed ID: 11416112
[TBL] [Abstract][Full Text] [Related]
7. Fibrinolytic status in acute coronary syndromes: evidence of differences in relation to clinical features and pathophysiological pathways.
Shantsila E; Montoro-García S; Tapp LD; Apostolakis S; Wrigley BJ; Lip GY
Thromb Haemost; 2012 Jul; 108(1):32-40. PubMed ID: 22538774
[TBL] [Abstract][Full Text] [Related]
8. Significantly increased concentration of soluble urokinase-type plasminogen activator receptor in the blood of patients with pelvic inflammatory disease.
Yeh YH; Wang PH; Lin LY; Tee YT; Chou MC; Yang SF; Tsai HT
Clin Chim Acta; 2013 Jan; 415():138-44. PubMed ID: 23117033
[TBL] [Abstract][Full Text] [Related]
9. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.
Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot A; van Tienoven DT; Beex LV; Sweep FC
Cancer; 2004 Aug; 101(3):486-94. PubMed ID: 15274061
[TBL] [Abstract][Full Text] [Related]
10. Plasma urokinase antigen and plasminogen activator inhibitor-1 antigen levels predict angiographic coronary restenosis.
Strauss BH; Lau HK; Bowman KA; Sparkes J; Chisholm RJ; Garvey MB; Fenkell LL; Natarajan MK; Singh I; Teitel JM
Circulation; 1999 Oct; 100(15):1616-22. PubMed ID: 10517732
[TBL] [Abstract][Full Text] [Related]
11. Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size.
Abe J; Urano T; Konno H; Erhan Y; Tanaka T; Nishino N; Takada A; Nakamura S
Cancer; 1999 Dec; 86(12):2602-11. PubMed ID: 10594855
[TBL] [Abstract][Full Text] [Related]
12. Role of the urokinase plasminogen activator system in patients with bacterial meningitis.
Winkler F; Kastenbauer S; Koedel U; Pfister HW
Neurology; 2002 Nov; 59(9):1350-5. PubMed ID: 12427882
[TBL] [Abstract][Full Text] [Related]
13. Urokinase and plasminogen activator-inhibitor (PAI-1) status in primary ovarian carcinomas and ovarian metastases compared to benign ovarian tumors as a function of histopathological parameters.
Hoffmann G; Pollow K; Weikel W; Strittmatter HJ; Bach J; Schaffrath M; Knapstein P; Melchert F; Pollow B
Clin Chem Lab Med; 1999 Jan; 37(1):47-54. PubMed ID: 10094378
[TBL] [Abstract][Full Text] [Related]
14. Concentrations of plasminogen activators and their inhibitors in blood preconceptionally, during and after pregnancy.
Coolman M; de Groot CJ; Steegers EA; Geurts-Moespot A; Thomas CM; Steegers-Theunissen RP; Sweep FC
Eur J Obstet Gynecol Reprod Biol; 2006; 128(1-2):22-8. PubMed ID: 16584829
[TBL] [Abstract][Full Text] [Related]
15. Expression of plasminogen activator inhibitors type 1 and type 3 and urokinase plasminogen activator protein and mRNA in breast cancer.
Castelló R; Landete JM; España F; Vázquez C; Fuster C; Almenar SM; Ramón LA; Radtke KP; Estellés A
Thromb Res; 2007; 120(5):753-62. PubMed ID: 17258797
[TBL] [Abstract][Full Text] [Related]
16. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
[TBL] [Abstract][Full Text] [Related]
17. [Effects of urokinase type plasminogen activator and plasminogen activator inhibitor-1 expressions on the formation of aneurysm of perimembranous ventricular septal defect].
Qian J; Li B; Yin M; Shen P; Sun K
Zhonghua Er Ke Za Zhi; 2015 Jun; 53(6):453-8. PubMed ID: 26310557
[TBL] [Abstract][Full Text] [Related]
18. Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 as a prognostic factor in human colorectal carcinomas.
Fujii T; Obara T; Tanno S; Ura H; Kohgo Y
Hepatogastroenterology; 1999; 46(28):2299-308. PubMed ID: 10521987
[TBL] [Abstract][Full Text] [Related]
19. Altered expression of urokinase-type plasminogen activator and plasminogen activator inhibitor in high-risk soft tissue sarcomas.
Benassi MS; Ponticelli F; Azzoni E; Gamberi G; Pazzaglia L; Chiechi A; Conti A; Spessotto P; Scapolan M; Pignotti E; Bacchini P; Picci P
Histol Histopathol; 2007 Sep; 22(9):1017-24. PubMed ID: 17523079
[TBL] [Abstract][Full Text] [Related]
20. [Expression of urokinase plasminogen activator, its receptor and plasminogen activator inhibitor type 1 in different types of atherosclerotic lesion in human aorta].
Solomatina MA; Plekhanova OS; Il'inskaia OP; Kalinina NI; Mikhaĭlova EV; Tsokolaeva ZI; Tararak EM; Naumov VG; Parfenova EV
Tsitologiia; 2004; 46(4):352-60. PubMed ID: 15346794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
